The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

Learn more about AbbVie’s response to COVID-19

Three women embrace while smiling

Committed to supporting an

Exceptional Patient Experience
with timely product access
and educational resources

SKYRIZI® Complete Logo

GIVING PATIENTS THE RESOURCES THEY NEED,
WHEN THEY NEED THEM

Enrolling your patients in Skyrizi Complete will provide your patients the support to start and stay on track with their prescribed treatment, including the resources below.

Help with access & treatment affordability

Access & Savings

Empower
Patients

Nurse Ambassadors

Insurance support when needed

Access Specialists

Help with access & treatment affordability

Access & Savings

SKYRIZI Complete can help your commercial patients save:

  • With the Skyrizi Complete Savings Card, your eligible commercially insured patients may pay as little as $5 per quarterly dose. Terms and Conditions of the copay assistance program apply
  • Skyrizi Complete may help eligible commercially insured patients experiencing initial coverage denials due to step therapy requirements access their prescribed therapy at no charge while coverage is established or during the appeals process. Eligibility criteria apply; call 1-866-SKYRIZI (1-866-759-7494) for more information. Terms and Conditions apply*
Speech bubble icon

Empower Patients

Nurse Ambassadors*

Our Nurse Ambassadors are the heart of SKYRIZI Complete

Nurse Ambassadors provide 1:1 support to help meet the unique needs of each individual patient, including:

  • Answering questions throughout the injection experience to help avoid disruptions
  • Helping patients make sense of their insurance coverage, helping them find ways to save on prescription costs, and connecting them with additional insurance expertise and resources designed around their prescribed treatment plan
  • Providing training to complement the training you have given them, along with supplemental injection training resources
  • Helping patients understand their roles in coordinating their treatment (including the delivery of their medication to their doctor’s office in time for their next injection)
  • The Skyrizi Complete Nurse Ambassadors have an average of more than 19 years of experience2

Call 1-866-SKYRIZI (1-866-759-7494) to have your patient connect with a Nurse Ambassador.


Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

DOWNLOAD OR EMAIL SKYRIZI COMPLETE ENROLLMENT AND PRESCRIPTION FORM

Empower Patients

Nurse Ambassadors

DOWNLOAD OR EMAIL SKYRIZI COMPLETE ENROLLMENT AND PRESCRIPTION FORM

Insurance support when needed

Access specialists

ACCESS SPECIALISTS HAVE EXPERTISE IN PAYER-SPECIFIC POLICIES AND PROCESSES:

  • Are knowledgeable on Medicare and commercial plans at a national, local, and program level
  • Can educate on payer prior authorization requirements and appeal processes so you can determine the best access solution for each patient’s unique situation
  • Can educate on potential options to consider based on each patient’s unique financial situation
  • Help navigate prescription delivery to ensure SKYRIZI is delivered to the office for the patient's appointment

Call to speak to an Access Specialist 1-877-COMPLETE (1-877-266-7538).

Call to speak to an Access Specialist 1-877-COMPLETE (1-877-266-7538).

*Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing health care professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

Eligibility: Available to patients with commercial insurance coverage for SKYRIZI® (risankizumab-rzaa) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit www.skyrizisavingscard.com. To learn about AbbVie's privacy practices and your privacy choices, visit www.abbvie.com/privacy.html.

Patients can track treatment with the

Skyrizi Complete App


The Complete App helps patients set reminders, prepare for upcoming doses, and access additional resources.

STREAMLINE Rx PROCESS FOR PATIENTS

Completepro.com


CompletePro.com can be used for Skyrizi Complete enrollment, electronic benefits verification and prior authorization, reauthorization, shipment tracking, and more to help your patients quickly start and stay on track with therapy.

Stay up to date on the latest SKYRIZI news and information


4 DOSES PER YEAR

4 doses per year after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)1

ACR20/50/70 RESPONSE RATES

At Week 24 and 1 year1,3,4

(ACR20 primary endpoint at Week 24)